Analysts Slash Boston Scientific Targets After Earnings Miss

Boston Scientific is the day's biggest analyst story. Three separate calls hit this morning, all pointing lower. Jefferies cut BSX from Buy to Hold and slashed its target from $60 to $46. Canaccord Genuity kept its Buy but pulled its target from $66 to $48. The consensus average target fell to $52.00 from $57.34, and the Hold count rose to 10 from 7. The stock's short interest sits at just 3% of free float, so this is a story about fundamental disappointment rather than a short squeeze.

Honeywell Aerospace also drew a consensus downgrade today. The average target edged down to $196.73 from $199.20, with the sell count ticking up. HONA trades at a $56bn market cap and carries a short interest of 2.4% of free float.

Visa got a brighter read. Macquarie's Paul Golding raised his target to $465 from $420, maintaining Buy. The consensus target across 36 analysts is wide, but the direction here is firmly constructive.

Boeing saw its Bernstein target drop to $223 from $278, a $55 cut while the Buy rating stayed. That reflects ongoing delivery uncertainty rather than a rating flip, but it is one of the larger dollar cuts of the session.

ServiceNow picked up a Macquarie target lift to $120 from $110, and Biogen got a Canaccord raise to $272 from $248. Both analysts held their ratings unchanged alongside the upgrades.

The clearest pattern today: medtech under pressure, payments and software getting the benefit of the doubt.